In the past, chronic hepatitis C was treated with interferon plus ribavirin tablets. However, because interferon itself has more side effects, takes longer to treat, is more expensive, and has restricted application in patients with cirrhosis, and has a higher chance of relapse at the end of the course of treatment, many patients have had to give up during the course of treatment. In early years, oral antiviral therapy has been available abroad, just like the treatment of chronic hepatitis B. It is greatly convenient for patients and has good efficacy and short course of treatment. However, few patients can afford it because it is very expensive. Domestic related drugs are also currently not able to be produced and sold. But since this year, the situation has changed, and generic drugs from neighboring countries, through online purchase or substitute purchase, are gradually entering the country, making a reliable treatment available for domestic patients with chronic hepatitis C, especially those who have cirrhosis. At present, the main oral drugs for hepatitis C are Sofosbuvir and Ledipavir, which can solve the treatment problems of most patients. The typing of the hepatitis C virus should be determined before treatment, and the drug regimen and course of treatment should be determined based on the typing. Chinese hepatitis C infection is usually dominated by type 1b and type 2a, and can be treated with sofosbuvir plus ribavirin, sofosbuvir plus ledipavir, often for 3 months for type 2a, and for type 1b according to the medication and whether there is cirrhosis, usually for 3-6 months, which is effective in more than 90% of patients. Because these drugs are currently used in China for a relatively short period of time, it is important to seek the guidance of an experienced physician and to do the necessary laboratory tests and examinations.